{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ozanimod+placebo", "query": { "intervention": "ozanimod placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ozanimod+placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T20:25:42.704Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03644576", "title": "Drug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart Rate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "ozanimod", "type": "DRUG" }, { "name": "Pseudoephedrine", "type": "DRUG" }, { "name": "ozanimod placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 54, "start_date": "2018-07-11", "completion_date": "2018-09-12", "has_results": false, "last_update_posted_date": "2019-05-30", "last_synced_at": "2026-09-13T20:25:42.704Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03644576" }, { "nct_id": "NCT03464097", "title": "A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Ozanimod", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 550, "start_date": "2018-06-27", "completion_date": "2024-10-03", "has_results": true, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-09-13T20:25:42.704Z", "location_count": 188, "location_summary": "Peoria, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 140 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Camarillo", "state": "California" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03464097" }, { "nct_id": "NCT02047734", "title": "Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Ozanimod", "type": "DRUG" }, { "name": "Ozanimod placebo", "type": "DRUG" }, { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Interferon beta-1a placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 1320, "start_date": "2013-12-03", "completion_date": "2017-04-13", "has_results": true, "last_update_posted_date": "2021-02-11", "last_synced_at": "2026-09-13T20:25:42.704Z", "location_count": 35, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02047734" }, { "nct_id": "NCT03694119", "title": "Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "Phenelzine", "type": "DRUG" }, { "name": "Tyramine", "type": "DRUG" }, { "name": "Phenelzine placebo", "type": "DRUG" }, { "name": "ozanimod placebo", "type": "DRUG" }, { "name": "ozanimod", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "25 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "25 Years to 55 Years" }, "enrollment_count": 92, "start_date": "2018-07-24", "completion_date": "2019-01-08", "has_results": false, "last_update_posted_date": "2019-07-19", "last_synced_at": "2026-09-13T20:25:42.704Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03694119" }, { "nct_id": "NCT06408259", "title": "Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Ozanimod", "type": "DRUG" }, { "name": "Fingolimod", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 194, "start_date": "2025-04-08", "completion_date": "2036-07-13", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-13T20:25:42.704Z", "location_count": 12, "location_summary": "Loma Linda, California • Sacramento, California • Tampa, Florida + 8 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06408259" }, { "nct_id": "NCT03440385", "title": "Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Ozanimod", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 606, "start_date": "2018-03-07", "completion_date": "2023-11-21", "has_results": true, "last_update_posted_date": "2024-12-05", "last_synced_at": "2026-09-13T20:25:42.704Z", "location_count": 81, "location_summary": "Scottsdale, Arizona • La Jolla, California • Lancaster, California + 67 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03440385" }, { "nct_id": "NCT03440372", "title": "Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Ozanimod", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 625, "start_date": "2018-02-27", "completion_date": "2024-10-01", "has_results": true, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-09-13T20:25:42.704Z", "location_count": 107, "location_summary": "Peoria, Arizona • North Little Rock, Arkansas • Camarillo, California + 84 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Camarillo", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Garden Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03440372" }, { "nct_id": "NCT01628393", "title": "Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Ozanimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 258, "start_date": "2012-09-18", "completion_date": "2016-05-11", "has_results": true, "last_update_posted_date": "2021-02-11", "last_synced_at": "2026-09-13T20:25:42.704Z", "location_count": 6, "location_summary": "Berkeley, California • Fresno, California • Sacramento, California + 3 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Akron", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01628393" }, { "nct_id": "NCT02294058", "title": "Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Ozanimod", "type": "DRUG" }, { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Placebo to ozanimod", "type": "DRUG" }, { "name": "Placebo to interferon beta-1a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 1346, "start_date": "2014-12-03", "completion_date": "2016-12-22", "has_results": true, "last_update_posted_date": "2020-11-25", "last_synced_at": "2026-09-13T20:25:42.704Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02294058" }, { "nct_id": "NCT02435992", "title": "Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "RPC1063", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1012, "start_date": "2015-06-17", "completion_date": "2020-06-17", "has_results": true, "last_update_posted_date": "2021-09-01", "last_synced_at": "2026-09-13T20:25:42.704Z", "location_count": 113, "location_summary": "Sun City, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 87 more", "locations": [ { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Costa Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02435992" } ] }